Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19

Abstract Nezulcitinib (TD‐0903), a lung‐selective pan-Janus‐associated kinase (JAK) inhibitor designed for inhaled delivery, is under development for treatment of acute lung injury associated with coronavirus disease 2019 (COVID‐19). This two‐part, double‐blind, randomized, placebo‐controlled, singl...

Full description

Saved in:
Bibliographic Details
Main Authors: Nathan D. Pfeifer (Author), Arthur Lo (Author), David L. Bourdet (Author), Kenneth Colley (Author), Dave Singh (Author)
Format: Book
Published: Wiley, 2021-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available